Balyasny Asset Management LLC Fulcrum Therapeutics, Inc. Transaction History
Balyasny Asset Management LLC
- $58 Billion
- Q3 2024
A detailed history of Balyasny Asset Management LLC transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 10,374 shares of FULC stock, worth $38,072. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,374
Previous 11,367
8.74%
Holding current value
$38,072
Previous $70,000
47.14%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding FULC
# of Institutions
148Shares Held
51.8MCall Options Held
6.91MPut Options Held
1.89M-
Ra Capital Management, L.P. Boston, MA10.2MShares$37.5 Million0.51% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA5.25MShares$19.3 Million2.43% of portfolio
-
Black Rock Inc. New York, NY4.8MShares$17.6 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT4.78MShares$17.5 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.27MShares$12 Million0.0% of portfolio
About Fulcrum Therapeutics, Inc.
- Ticker FULC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,038,900
- Market Cap $191M
- Description
- Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...